Inorganic nitrate reduces contrast-induced nephropathy in high-risk patients

Inorganic nitrate reduces contrast-induced nephropathy (CIN), improves renal outcomes and reduces cardiac events compared to placebo in patients at risk of renal injury undergoing coronary angiography for acute coronary syndrome, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

Imvotamab by IGM Biosciences for Rheumatoid Arthritis: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

December 22, 2023

Eisai, Biogen make case for long-term use of Alzheimer’s drug Leqembi with new data

Patients with early Alzheimer’s disease treated with a medication developed by Eisai and Biogen for up to three years experienced less cognitive decline than what’s

July 31, 2024

The colonoscopies were free. But the ‘surgical trays’ came with $600 price tags.

Chantal Panozzo and her husband followed their primary care doctors’ orders last year after they both turned 45, now the recommended age to start screening

January 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.